Associate Clinical Professor in Paediatric Oncology
University of Birmingham, United Kingdom
Dr Susanne Gatz is a paediatric oncologist with strong scientific/ translational leaning who aims to combine her clinical expertise in solid tumours and clinical trials with her laboratory interests and expertise into translational research into DNA repair and sarcoma to ultimately identify better treatments for children with cancer, in particular sarcomas.
Susanne joined the University of Birmingham as Associate Professor in Paediatric Oncology in October 2018 and holds a honorary contract as paediatric oncology consultant with the Birmingham Children's Hospital. She is based at the Cancer Research UK Clinical Trials Unit within the Institute of Cancer and Genomic Sciences and is involved in the paediatric cancer trial portfolio with focus on sarcomas. She is leading on taking forward novel agents in rhabdomyosarcoma and is CRCTU lead for the Regorafenib relapse study within FaR-RMS. With regards to clinical research into DNA repair inhibitors Susanne has developed arm D and arm N in the paediatric Acse-ESMART (NCT02813135) stratified medicine platform trial; these trial arms are investigating the PARP inhibitor Olaparib in combination with irinotecan or ATR inhibitor in paediatric patients with selected genomic alterations. She further has built links with several labs at the ICGS and is co-leading on translational projects on Rhabdomyosarcoma and Ewing sarcoma including drug testing and biomarker development in an innovative rhabdomyosarcoma embryo zebrafish xenograft model with Prof. Mueller and Dr. Wragg.
Relevant Memberships (selection): National: Novel Agents subgroup of the Childrens’ Cancer and Leukaemia NCRI Clinical Studies Group since 2017, Genomics Test Evaluation Working Group for Cancer of NHS England since 2022; International: European paediatric Soft tissue Sarcoma Study Group (EpSSG) Phase I/II committee since 2013 (chair since 2021), Scientific Committee of SIOP since 2018, Innovative Therapies for Children with Cancer (ITCC) solid tumour steering committee since 2021, Euro Ewing Consortium (EEC) since 2022.
